Premium
P1‐050: ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW STUDY: A DELAY‐OF‐ONSET PHASE 3 CLINICAL TRIAL
Author(s) -
Chiang Carl,
Alexander Robert,
Welsh-Bohmer Kathleen A.,
Plassman Brenda L.,
Romero Heather,
Hayden Kathleen M.,
Keefe Richard SE.,
Atkins Alexandra S.,
Harrigan Patrick,
O'Neil Janet,
Culp Meredith,
Walter Ryan,
Wu Jingtao,
Randle LaDonna,
Haneline Stephen,
Yarbrough Deborah,
Metz Craig,
Burns Daniel K.,
Saunders Ann M.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - Czech
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.051
Subject(s) - clinical trial , cognition , clinical endpoint , medicine , neuropsychology , psychology , disease , randomized controlled trial , psychiatry , pediatrics
Carl Chiang, PhD1, Robert Alexander, MD2, Kathleen A. Welsh-Bohmer, PhD3,4, Brenda L. Plassman, PhD3,4, Heather Romero, PhD3, Kathleen M. Hayden, PhD3,4, Richard S.E. Keefe, PhD4, 5, Alexandra S. Atkins, PhD5, Patrick Harrigan, BChE6*, Janet O’Neil, MBA6, Meredith Culp, BS6, Ryan Walter, BS7, Jingtao Wu, PhD6, LaDonna Randle, BA7, Stephen Haneline, MS1, Deborah Yarbrough, MS, MBA6, Daniel K. Burns, PhD1, Ann M. Saunders, PhD1, for the TOMMORROW Study Investigators 1Zinfandel Pharmaceuticals, Inc., Durham, NC, USA; 2Takeda Development Center Americas, Inc., Cambridge, MA, USA; 3Duke University Bryan ADRC, Durham, NC, USA; 4Department of Psychiatry, Duke University Medical Center, Durham, NC, USA; 5NeuroCog Trials, Durham, NC, USA; 6Takeda Development Center Americas, Inc., Deerfield, IL, USA; 7PRA Health Science, Deerfield, IL, USA